WO1999030703A1 - Use of formoterol in medicament for inflammation/allergy in upper airways - Google Patents

Use of formoterol in medicament for inflammation/allergy in upper airways Download PDF

Info

Publication number
WO1999030703A1
WO1999030703A1 PCT/SE1998/002278 SE9802278W WO9930703A1 WO 1999030703 A1 WO1999030703 A1 WO 1999030703A1 SE 9802278 W SE9802278 W SE 9802278W WO 9930703 A1 WO9930703 A1 WO 9930703A1
Authority
WO
WIPO (PCT)
Prior art keywords
formoterol
active ingredient
inflammatory
allergic rhinitis
solvate
Prior art date
Application number
PCT/SE1998/002278
Other languages
French (fr)
Inventor
Carl Göran PERSSON
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to AU18971/99A priority Critical patent/AU1897199A/en
Priority to EP98963701A priority patent/EP1037620A1/en
Priority to JP2000538686A priority patent/JP2002508319A/en
Publication of WO1999030703A1 publication Critical patent/WO1999030703A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Definitions

  • the invention provides the use of formoterol in the treatment of inflammatory and allergic conditions in the upper airways of human beings.
  • Inflammatory and allergic conditions in the upper airways include conditions such as rhinitis, sinusitis and nasal polyps. Conditions such as these are conventionally treated by corticosteroid nasal sprays. The problem with using corticosteroids to treat these conditions is that it takes some time before they take effect.
  • US-A-4,975,466 to Ciba-Geigy relates to pharmaceutical preparations containing formo- terol or one of its pharmaceutically acceptable salts, especially its semifumarate, for treatment of inflammatory skin diseases.
  • the preparations are mainly used for topical, i.e. dermal, application, to the skin and/or mucous membrane, since formoterol is said to have a very pronounced antiphlogistic (dermally phlogistatic) topically anti-inflammatory, action. More specifically, the preparations are intended for external use on the outer skin, including the conjunctiva of the eyeball, the lips and the genital and anal region.
  • the present invention is directed to the use of formoterol, or pharmaceutically acceptable salts or solvates thereof for manufacturing medicaments suitable for use in the treatment of an inflammatory and or allergic condition in the upper airways of a human being.
  • the active ingredient is formoterol fumarate dihydrate.
  • an active ingredient which is formo- terol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt in the manufacture of a medicament for use in the treatment of an inflammatory and/or allergic condition in the upper airways of a human being.
  • a method of treating a patient suffering from an inflammatory and/or allergic condition in the upper airways which comprises administering to the patient a therapeutically effective amount of the active ingredient, wherein the patient is a human being.
  • composition comp- rising the active ingredient in association with one or more pharmaceutically acceptable diluent, carrier or additive, which composition is for use in the treatment of an inflammatory and/or allergic condition in the upper airways of human beings.
  • Formoterol is an adrenoreceptor agonist which selectively stimulates ⁇ 2 -receptors, with the formula (N-[2-hydroxy-5-[l-hydroxy-2-[[2-(4-methoxyphenyl)-l-methyl-ethyl]-amino]- ethyl]-phenyl]-formamide. It has surprisingly been found to be effective in the treatment of inflammatory and allergic conditions in the upper airways of human beings. Inhaled formoterol has the advantage that it both acts rapidly, usually within minutes, and exerts a prolonged effect of up to 12 hours.
  • Suitable physiologically acceptable salts of formoterol include acid addition salts derived from inorganic and organic acids, for example the chloride, bromide, sulfate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulfonate, methanesulfonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalene-carboxylate oroleate salts or solvates thereof.
  • the active ingredient is preferably formoterol fumarate, especially the dihydrate.
  • Formoterol pharmaceutically acceptable salts and solvates of formoterol, and solvates of such salts can be prepared by the methods described in US-A-5,434,304 to Astra and DE- A-2,305,092 to Yamanouchi.
  • the preferred daily dose of the active ingredient is from 5 to 250 nmol (preferably from 15 to 120 nmol).
  • the active ingredient is formoterol fumarate dihydrate the preferred daily dose is from 3 to 96 ⁇ g, more preferably from 3 to 48 ⁇ g and most preferably from 3 to 24 ⁇ g per day.
  • suitable unit doses include 3, 4.5, 6, 9 and 12 ⁇ g of formoterol fumarate dihydrate.
  • the invention provides a new and surprisingly effective treatment for inflammatory and/or allergic conditions in the upper airways of a human being.
  • the conditions treatable by the invention are preferably in the nose and paranasal sinus. They include
  • the active ingredient is used in admixture with one or more pharmaceutically acceptable additives, diluents or carriers, preferably in an amount of from 50 ⁇ g to 25 mg per dose, more preferably in an amount of from 50 ⁇ g to 10 mg, most preferably in an amount of from 100 to 4000 ⁇ g.
  • suitable diluents or carriers include lactose, dextran, mannitol and glucose.
  • lactose is used, especially as the monohydrate.
  • the active ingredient used in the invention is preferably in the form of a dry powder, more preferably a finely divided, e.g. amicronized, dry powder, e.g. having a mass median diameter of less than 10 ⁇ m, for example from 1 to 5 ⁇ m, most preferably an agglomerated micronized dry powder. Preferably at least 90% of the powder particles have a size below 15 ⁇ m.
  • the finely divided active ingredients may be in the form of an ordered mixture with one or more pharmaceutically acceptable additives, diluents or carriers.
  • An ordered mixture is the combination of a finely divided active ingre- dominant with coarse particles of a pharmaceutically acceptable additive, diluent and/or carrier.
  • the ingredients used in the invention can be obtained in these preferred forms using methods known to those skilled in the art.
  • EXAMPLE 1 10 parts of formoterol fumarate dihydrate was mixed with 990 parts of lactose mono- hydrate. The blend was micronized using a high pressure air jet mill and then conditioned using the process of EP-A-717616. The mixture was then spheronised using the process of EP-A-721331, divided into parts, each of which were filled into the storage compartment of a Turbuhaler fitted with a dosing disc such that it administered, when activated, a unit dose of 6 ⁇ g.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides the use of an active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt in the manufacture of a medicament for use in the treatment of an inflammatory and/or allergic condition in the upper airways of a human being.

Description

USE OF FORMOTEROL IN MEDICAMENT FOR INFLAMMATION/ALLERGY IN UPPER AIRWAYS
FIELD OF THE INVENTION
The invention provides the use of formoterol in the treatment of inflammatory and allergic conditions in the upper airways of human beings.
BACKGROUND OF THE INVENTION
Inflammatory and allergic conditions in the upper airways include conditions such as rhinitis, sinusitis and nasal polyps. Conditions such as these are conventionally treated by corticosteroid nasal sprays. The problem with using corticosteroids to treat these conditions is that it takes some time before they take effect.
The use of a beta-2-adrenostimulant, fenoterol, to treat seasonal allergic rhinitis has been investigated. It was found that it had an insignificant effect upon nasal hypersecretion and nasal blockage caused by the rhinitis (Borum et al, Allergy 42, (1987), pp. 141-145).
US-A-4,975,466 to Ciba-Geigy relates to pharmaceutical preparations containing formo- terol or one of its pharmaceutically acceptable salts, especially its semifumarate, for treatment of inflammatory skin diseases. The preparations are mainly used for topical, i.e. dermal, application, to the skin and/or mucous membrane, since formoterol is said to have a very pronounced antiphlogistic (dermally phlogistatic) topically anti-inflammatory, action. More specifically, the preparations are intended for external use on the outer skin, including the conjunctiva of the eyeball, the lips and the genital and anal region. There is no information about use of formoterol or preparations thereof for alleviating inflammatory and/or allergic conditions in the upper airways. C. Advenier et al, Br. J. Pharmacol., 105 (1995), pp. 792-798 relates to the effects of the β 2 -adrenoceptor agonists, salbutamol and formoterol, on the increase of micro-vascular permeability induced by histamine or bradykinin in guinea-pig airways. In the nasal mucosa, only salbutamol in doses of 30 μg/kg showed a significant inhibitory effect against histamine whereas formoterol 10 μg/kg significantly increased the effects of histamine in a dramatic manner. Therefore, Advenier et al strongly indicates that use of formoterol in the treatment of inflammatory and/or allergic conditions in the upper airways should be avoided.
Accordingly mere is a need for an effective treatment which has a faster onset time and a long duration.
SUMMARY OF THE INVENTION
The present invention is directed to the use of formoterol, or pharmaceutically acceptable salts or solvates thereof for manufacturing medicaments suitable for use in the treatment of an inflammatory and or allergic condition in the upper airways of a human being.
According to a preferred embodiment of the invention, the active ingredient is formoterol fumarate dihydrate.
DETAILED DESCRIPTION OF THE INVENTION
According to the invention there is provided the use of an active ingredient which is formo- terol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt in the manufacture of a medicament for use in the treatment of an inflammatory and/or allergic condition in the upper airways of a human being.
According to the invention there is also provided a method of treating a patient suffering from an inflammatory and/or allergic condition in the upper airways which comprises administering to the patient a therapeutically effective amount of the active ingredient, wherein the patient is a human being.
According to the invention there is further provided a pharmaceutical composition comp- rising the active ingredient in association with one or more pharmaceutically acceptable diluent, carrier or additive, which composition is for use in the treatment of an inflammatory and/or allergic condition in the upper airways of human beings.
Formoterol is an adrenoreceptor agonist which selectively stimulates β2-receptors, with the formula (N-[2-hydroxy-5-[l-hydroxy-2-[[2-(4-methoxyphenyl)-l-methyl-ethyl]-amino]- ethyl]-phenyl]-formamide. It has surprisingly been found to be effective in the treatment of inflammatory and allergic conditions in the upper airways of human beings. Inhaled formoterol has the advantage that it both acts rapidly, usually within minutes, and exerts a prolonged effect of up to 12 hours.
Suitable physiologically acceptable salts of formoterol include acid addition salts derived from inorganic and organic acids, for example the chloride, bromide, sulfate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulfonate, methanesulfonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalene-carboxylate oroleate salts or solvates thereof. The active ingredient is preferably formoterol fumarate, especially the dihydrate.
Formoterol, pharmaceutically acceptable salts and solvates of formoterol, and solvates of such salts can be prepared by the methods described in US-A-5,434,304 to Astra and DE- A-2,305,092 to Yamanouchi.
The preferred daily dose of the active ingredient is from 5 to 250 nmol (preferably from 15 to 120 nmol). When the active ingredient is formoterol fumarate dihydrate the preferred daily dose is from 3 to 96 μg, more preferably from 3 to 48 μg and most preferably from 3 to 24 μg per day. Examples of suitable unit doses include 3, 4.5, 6, 9 and 12 μg of formoterol fumarate dihydrate.
The invention provides a new and surprisingly effective treatment for inflammatory and/or allergic conditions in the upper airways of a human being. The conditions treatable by the invention are preferably in the nose and paranasal sinus. They include
- seasonal allergic rhinitis which is pollinosis caused by pollens from ragweed, birch, grass, cedar or other plants
- perennial allergic rhinitis caused by e.g. dust mites (Dermatophagoides pteronyssinus and D. farinae), cockroaches and mammals such as cats, dogs and horses
- perennial non-allergic rhinitis
- nasal polyps, as well as prevention of post surgical nasal polyps
- chronic sinusitis
- recurrent sinusitis and - hypertrophic adenoids.
Preferably the active ingredient is used in admixture with one or more pharmaceutically acceptable additives, diluents or carriers, preferably in an amount of from 50 μg to 25 mg per dose, more preferably in an amount of from 50 μg to 10 mg, most preferably in an amount of from 100 to 4000 μg. Examples of suitable diluents or carriers include lactose, dextran, mannitol and glucose. Preferably lactose is used, especially as the monohydrate.
The active ingredient used in the invention is preferably in the form of a dry powder, more preferably a finely divided, e.g. amicronized, dry powder, e.g. having a mass median diameter of less than 10 μm, for example from 1 to 5 μm, most preferably an agglomerated micronized dry powder. Preferably at least 90% of the powder particles have a size below 15 μm. As an alternative to agglomeration the finely divided active ingredients may be in the form of an ordered mixture with one or more pharmaceutically acceptable additives, diluents or carriers. An ordered mixture is the combination of a finely divided active ingre- dient with coarse particles of a pharmaceutically acceptable additive, diluent and/or carrier. The ingredients used in the invention can be obtained in these preferred forms using methods known to those skilled in the art.
The invention will be illustrated by the following examples which are not intended to limit the scope of the invention.
EXAMPLES
EXAMPLE 1 10 parts of formoterol fumarate dihydrate was mixed with 990 parts of lactose mono- hydrate. The blend was micronized using a high pressure air jet mill and then conditioned using the process of EP-A-717616. The mixture was then spheronised using the process of EP-A-721331, divided into parts, each of which were filled into the storage compartment of a Turbuhaler fitted with a dosing disc such that it administered, when activated, a unit dose of 6 μg.
Example 2
20 parts of formoterol fumarate dihydrate was mixed with 980 parts of lactose monohydrate. The blend was micronized using a high pressure air jet mill and then conditioned using the process of EP-A-717616. The mixture was then spheronized using the process of EP-A-721331, divided into parts, each of which were filled into the storage compartment of a Turbuhaler fitted with a dosing disc such that it administered, when activated, a unit dose of 12 μg.

Claims

1. Use of an active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt in the manufacture of a medicament for use in the treatment of an inflammatory and/or allergic condition in the upper airways of a human being.
2. Use according to claim 1, wherein the active ingredient is formoterol fumarate dihydrate.
3. Use according to claim 1 or 2, wherein the inflammatory and/or allergic condition is selected from the group consisting of seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, chronic sinusitis, recurrent sinusitis and hypertrophic adenoids.
4. Use according to any previous claim, wherein the active ingredient is a finely divided dry powder, preferably an agglomerated micronized dry powder.
5. Use according to claim 4, wherein the finely divided dry powder has a mass median diameter of less than 10 ╬╝m, preferably in the range of from 1 to 5 ╬╝m.
6. Use according to any previous claim, wherein the daily dose of the active ingredient is from 5 to 250 nmol, preferably from 15 to 120 nmol.
7. A method of treating a human patient suffering from an inflammatory and/or allergic condition in the upper airways, which comprises administering to the human patient a therapeutically effective amount of an active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt.
8. The method according to claim 7, wherein the active ingredient is formoterol fumarate dihydrate.
9. The method according to claim 7 or 8, wherein the inflammatory and/or allergic condition is selected from the group consisting of seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, chronic sinusitis, recurrent sinusitis and hypertrophic adenoids.
10. A pharmaceutical composition comprising an active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt in admixture with a pharmaceutically acceptable diluent, carrier and/or additive, which composition is for use in the treatment of an inflammatory and/or allergic condition in the upper airways of a human being.
11. The pharmaceutical composition according to claim 10, wherein the active ingredient is formoterol fumarate dihydrate.
12. The pharmaceutical composition according to any one of claims 10 or 11, wherein the active ingredient is a finely divided dry powder, preferably an agglomeratedmicronized dry powder or an ordered mixture.
13. The pharmaceutical composition according to claim 12, wherein the finely divided dry powder has a mass median diameter of less than 10 ╬╝m, preferably in the range of from 1 to 5 ╬╝m.
14. The pharmaceutical composition according to any one of claims 10 to 13, wherein the dose of active ingredient in admixture with a pharmaceutically acceptable diluent, carrier and/or additive, lies in the range of from 50 ╬╝g to 25 mg, preferably from 100 ╬╝g to 4 mg.
15. The pharmaceutical composition according to any one of claims 10 to 14, wherein the inflammatory and/or allergic condition is selected from the group consisting of seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, chronic sinusitis, recurrent sinusitis and hypertrophic adenoids.
PCT/SE1998/002278 1997-12-12 1998-12-10 Use of formoterol in medicament for inflammation/allergy in upper airways WO1999030703A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU18971/99A AU1897199A (en) 1997-12-12 1998-12-10 Use of formoterol in medicament for inflammation/allergy in upper airways
EP98963701A EP1037620A1 (en) 1997-12-12 1998-12-10 Use of formoterol in medicament for inflammation/allergy in upper airways
JP2000538686A JP2002508319A (en) 1997-12-12 1998-12-10 Use of formoterol in drugs for inflammation / allergy in the upper respiratory tract

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704644-5 1997-12-12
SE9704644A SE9704644D0 (en) 1997-12-12 1997-12-12 New use

Publications (1)

Publication Number Publication Date
WO1999030703A1 true WO1999030703A1 (en) 1999-06-24

Family

ID=20409370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1998/002278 WO1999030703A1 (en) 1997-12-12 1998-12-10 Use of formoterol in medicament for inflammation/allergy in upper airways

Country Status (5)

Country Link
EP (1) EP1037620A1 (en)
JP (1) JP2002508319A (en)
AU (1) AU1897199A (en)
SE (1) SE9704644D0 (en)
WO (1) WO1999030703A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032163A1 (en) * 1999-11-03 2001-05-10 Astrazeneca Ab NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST
WO2003063843A1 (en) * 2002-02-01 2003-08-07 Astrazeneca Ab Composition for inhalation
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2004106279A2 (en) 2003-05-27 2004-12-09 Theravance, Inc. CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST
US7348362B2 (en) 2003-07-10 2008-03-25 Dey, L.P. Bronchodilating β-agonist compositions and methods
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2263998A1 (en) 2005-05-20 2010-12-22 Almirall S.A. Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
US8178679B2 (en) 2007-11-28 2012-05-15 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors
US8283342B2 (en) 2007-02-09 2012-10-09 Almirall S.A. Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
US8524908B2 (en) 2009-03-12 2013-09-03 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
US8623851B2 (en) 2001-04-17 2014-01-07 Mylan Specialty L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2014095920A1 (en) 2012-12-18 2014-06-26 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
US9108918B2 (en) 2011-10-07 2015-08-18 Almirall, S.A. Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate
US9315463B2 (en) 2010-05-13 2016-04-19 Almirall, S.A. Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
US9346759B2 (en) 2012-03-20 2016-05-24 Almirall, S.A. Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor
US9562039B2 (en) 2013-02-27 2017-02-07 Almirall, S.A. Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities
US9579316B2 (en) 2013-07-25 2017-02-28 Almirall, S.A. Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities
US10005771B2 (en) 2014-09-26 2018-06-26 Almirall, S.A. Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
US10456390B2 (en) 2013-07-25 2019-10-29 Almirall, S.A. Combinations comprising MABA compounds and corticosteroids

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019198A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019198A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BR. J. PHARMACOL., Volume 105, 1992, C. ADVENIER et al., "Formoterol and Salbutamol Inhibit Bradykinin- and Histamine-Induced Airway Microvascular Leakage in Guinea-Pig", pages 792-798. *
BRITISH JOURNAL OF PHARMACOLOGY, Volume 116, 1995, STELLA R. O'DONNELL et al., "The Effects of Formoterol on Plasma Exudation Produced by a Localized Acute Inflammatory Response to Bradykinin in the Tracheal Mucosa of Rats In Vivo", pages 1571-1576. *
JOURNAL OF APPLIED PHYSIOLOGY, Volume 77, 1994, J.J. BOWDEN et al., "Inhibition of Neutrophil and Eosinophil Adhesion to Venules of Rat Trachea by beta2-Adrenergic Agonist Formoterol", pages 397-405. *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032163A1 (en) * 1999-11-03 2001-05-10 Astrazeneca Ab NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US8623851B2 (en) 2001-04-17 2014-01-07 Mylan Specialty L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US9597396B2 (en) 2001-04-17 2017-03-21 Mylan Specialty Lp Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2003063843A1 (en) * 2002-02-01 2003-08-07 Astrazeneca Ab Composition for inhalation
WO2004106279A2 (en) 2003-05-27 2004-12-09 Theravance, Inc. CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST
US7465756B2 (en) 2003-07-10 2008-12-16 Jpmorgan Chase Bank, N.A. Bronchodilating beta-agonist compositions and methods
US7473710B2 (en) 2003-07-10 2009-01-06 Jpmorgan Chase Bank, N.A. Bronchodilating beta-agonist compositions and methods
US7541385B2 (en) 2003-07-10 2009-06-02 Chaudry Imtiaz A Bronchodilating β-agonist compositions and methods
US7348362B2 (en) 2003-07-10 2008-03-25 Dey, L.P. Bronchodilating β-agonist compositions and methods
US7462645B2 (en) 2003-07-10 2008-12-09 Jpmorgan Chase Bank, N.A. Bronchodilating beta-agonist compositions and methods
US9730890B2 (en) 2003-07-10 2017-08-15 Mylan Pharmaceuticals, Inc. Bronchodilating beta-agonist compositions and methods
US8242177B2 (en) 2005-05-20 2012-08-14 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor
US7964615B2 (en) 2005-05-20 2011-06-21 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor
EP2263998A1 (en) 2005-05-20 2010-12-22 Almirall S.A. Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor
US8283342B2 (en) 2007-02-09 2012-10-09 Almirall S.A. Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor
US8178679B2 (en) 2007-11-28 2012-05-15 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
US8524908B2 (en) 2009-03-12 2013-09-03 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2011141180A1 (en) 2010-05-13 2011-11-17 Almirall, S.A. NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
US9643961B2 (en) 2010-05-13 2017-05-09 Almirall, S.A. Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities
US9315463B2 (en) 2010-05-13 2016-04-19 Almirall, S.A. Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
US9108918B2 (en) 2011-10-07 2015-08-18 Almirall, S.A. Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
WO2013068554A1 (en) 2011-11-11 2013-05-16 Almirall, S.A. New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities
US10300072B2 (en) 2011-11-11 2019-05-28 Almirall, S.A. Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
US9233108B2 (en) 2011-11-11 2016-01-12 Almirall, S.A. Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
US9549934B2 (en) 2011-11-11 2017-01-24 Almirall, S.A. Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
US9757383B2 (en) 2011-11-11 2017-09-12 Almirall, S.A. Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
WO2013068552A1 (en) 2011-11-11 2013-05-16 Almirall, S.A. NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES
US9346759B2 (en) 2012-03-20 2016-05-24 Almirall, S.A. Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor
US9518050B2 (en) 2012-12-18 2016-12-13 Almirall, S.A. Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity
WO2014095920A1 (en) 2012-12-18 2014-06-26 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
US9562039B2 (en) 2013-02-27 2017-02-07 Almirall, S.A. Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities
US9579316B2 (en) 2013-07-25 2017-02-28 Almirall, S.A. Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities
US10456390B2 (en) 2013-07-25 2019-10-29 Almirall, S.A. Combinations comprising MABA compounds and corticosteroids
US10005771B2 (en) 2014-09-26 2018-06-26 Almirall, S.A. Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

Also Published As

Publication number Publication date
JP2002508319A (en) 2002-03-19
EP1037620A1 (en) 2000-09-27
AU1897199A (en) 1999-07-05
SE9704644D0 (en) 1997-12-12

Similar Documents

Publication Publication Date Title
EP1037620A1 (en) Use of formoterol in medicament for inflammation/allergy in upper airways
US9295644B2 (en) Methods and compositions for treating asthma
US8461211B2 (en) Use for budesonide and formoterol
AU2005316687B2 (en) Compositions and methods for pulmonary conditions
EP0871450A1 (en) New combination
CH680983A5 (en)
US6369115B1 (en) Stabilized powder formulations
JP5492072B2 (en) Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention and / or treatment of asthma exacerbations
AU8135098A (en) New combination of antiasthma medicaments
AU3707202A (en) New use for budesonide and formoterol
MXPA99011676A (en) New combination of antiasthma medicaments

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09230711

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998963701

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998963701

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998963701

Country of ref document: EP